T-cell acute lymphoblastic leukemia

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 13:51, 24 August 2015 by Jwarner (talk | contribs) (Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is th...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

5 regimens on this page
6 variants on this page


Note that many of the regimens used to treat this disease are generic to acute lymphoblastic leukemia; this page contains regimens that are specific to T-cell acute lymphoblastic leukemia (a.k.a. T-cell lymphoblastic lymphoma when primarily nodal-based).

Relapsed/Refractory

Nelarabine (Arranon)

back to top

Regimen

Study Evidence
DeAngelo et al. 2007 (CALGB 19801) Phase II

See paper for details about the schedule.

21-day cycle x 3 to 4 cycles (or delayed for count recovery)

References

  1. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. Epub 2007 Mar 7. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=T-cell_acute_lymphoblastic_leukemia&oldid=8373"